79
IRUS Total
Downloads
  Altmetric

Integrated systems-genetic analyses reveal a network target for delaying glioma progression

File Description SizeFormat 
acn3.50850.pdfPublished version4.9 MBAdobe PDFView/Open
Title: Integrated systems-genetic analyses reveal a network target for delaying glioma progression
Authors: Laaniste, L
Srivastava, P
Stylianou, T
Syed, N
Cases-Cunillera, S
Shkura, K
Zeng, Q
Rackham, O
Langley, S
Delahaye-Duriez, A
O'Neill, K
Williams, M
Becker, A
Roncaroli, F
Petretto, E
Johnson, M
Item Type: Journal Article
Abstract: Objective To identify a convergent, multitarget proliferation characteristic for astrocytoma transformation that could be targeted for therapy discovery. Methods Using an integrated functional genomics approach, we prioritized networks associated with astrocytoma progression using the following criteria: differential co‐expression between grade II and grade III IDH1‐mutated and 1p/19q euploid astrocytomas, preferential enrichment for genetic risk to cancer, association with patient survival and sample‐level genomic features. Drugs targeting the identified multitarget network characteristic for astrocytoma transformation were computationally predicted using drug transcriptional perturbation data and validated using primary human astrocytoma cells. Results A single network, M2, consisting of 177 genes, was associated with glioma progression on the basis of the above criteria. Functionally, M2 encoded physically interacting proteins regulating cell cycle processes and analysis of genome‐wide gene‐regulatory interactions using mutual information and DNA–protein interactions revealed the known regulators of cell cycle processes FoxM1, B‐Myb, and E2F2 as key regulators of M2. These results suggest functional disruption of M2 via gene mutation or altered expression as a convergent pathway regulating astrocytoma transformation. By considering M2 as a multitarget drug target regulating astrocytoma transformation, we identified several drugs that are predicted to restore M2 expression in anaplastic astrocytoma toward its low‐grade profile and of these, we validated the known antiproliferative drug resveratrol as down‐regulating multiple nodes of M2 including at nanomolar concentrations achievable in human cerebrospinal fluid by oral dosing. Interpretation Our results identify M2 as a multitarget network characteristic for astrocytoma progression and encourage M2‐based drug screening to identify new compounds for preventing glioma transformation.
Issue Date: 1-Sep-2019
Date of Acceptance: 28-Jun-2019
URI: http://hdl.handle.net/10044/1/71755
DOI: 10.1002/acn3.50850
ISSN: 2328-9503
Publisher: Wiley Open Access
Start Page: 1616
End Page: 1638
Journal / Book Title: Annals of Clinical and Translational Neurology
Volume: 6
Issue: 9
Copyright Statement: © 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
Sponsor/Funder: UCB Biopharma SPRL
Funder's Grant Number: PO - 4400320473
Keywords: Science & Technology
Life Sciences & Biomedicine
Clinical Neurology
Neurosciences
Neurosciences & Neurology
CHEMOPREVENTIVE AGENT RESVERATROL
NF-KAPPA-B
CELL-CYCLE
TRANSCRIPTION FACTOR
LEVEL ANALYSIS
GRADE GLIOMA
CANCER
COMPLEX
EXPRESSION
FOXM1
Publication Status: Published
Online Publication Date: 2019-08-17
Appears in Collections:Department of Brain Sciences